<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_TAS_Taipei_Validated skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><DIV id="top_title"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:TAS Taipei/Validated</SPAN></H1></DIV><DIV id="HQ_page"><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><DIV class="return"><H1>X</H1></DIV><DIV class="yellow"><DIV class="box right"><DIV class="box2 right project" href="https://2017.igem.org/Team:TAS_Taipei/Background"><H6 class="navCap">Project</H6></DIV><DIV class="box2 right experiment" href="https://2017.igem.org/Team:TAS_Taipei/Experimental_Summary"><H6 class="navCap">Experiments</H6></DIV><DIV class="box2 right modeling" href="https://2017.igem.org/Team:TAS_Taipei/Model"><H6 class="navCap">Modeling</H6></DIV><DIV class="box2 right prototype" href="https://2017.igem.org/Team:TAS_Taipei/Applied_Design"><H6 class="navCap">Prototype</H6></DIV><DIV class="box2 right policy" href="https://2017.igem.org/Team:TAS_Taipei/Human_Practices"><H6 class="navCap">Human Practices</H6></DIV><DIV class="box2 right biosafety" href="https://2017.igem.org/Team:TAS_Taipei/Safety"><H6 class="navCap">Safety</H6></DIV><DIV class="box2 right about" href="https://2017.igem.org/Team:TAS_Taipei/Team"><H6 class="navCap">About Us</H6></DIV><DIV class="box2 right acknowledgments" href="https://2017.igem.org/Team:TAS_Taipei/Attributions"><H6 class="navCap">Attributions</H6></DIV></DIV><DIV class="blue"><DIV class="box3 left project" href="https://2017.igem.org/Team:TAS_Taipei/Background"><H1>Project</H1></DIV><DIV class="box3 left experiment" href="https://2017.igem.org/Team:TAS_Taipei/Experimental_Summary"><H1>Experiment</H1></DIV><DIV class="box3 left modeling" href="https://2017.igem.org/Team:TAS_Taipei/Model"><H1>Modeling</H1></DIV><DIV class="box3 left prototype" href="https://2017.igem.org/Team:TAS_Taipei/Applied_Design"><H1>Prototype</H1></DIV><DIV class="box3 left policy" href="https://2017.igem.org/Team:TAS_Taipei/Human_Practices"><H1>Human Practice</H1></DIV><DIV class="box3 left biosafety" href="https://2017.igem.org/Team:TAS_Taipei/Safety"><H1>Safety</H1></DIV><DIV class="box3 left about" href="https://2017.igem.org/Team:TAS_Taipei/Team"><H1>About Us</H1></DIV><DIV class="box3 left acknowledgments" href="https://2017.igem.org/Team:TAS_Taipei/Attributions"><H1>Attributions</H1></DIV></DIV></DIV><DIV class="cv" id="cv"><DIV class="row"><NAV class="pageNav col-lg-1" id="navbar"><UL class="nav"><LI><A href="#BBa" class="pageNavBig">BBa_K2229400</A></LI><LI><A href="#CR" class="pageNavBig">Can PR Bind Citrate-Capped NPs?</A></LI></UL></NAV><DIV class="white col-lg-2">
                hi
            </DIV><DIV class="col-lg-10"><HEADER><DIV class="row"><H1 class="name col-lg-12">VALIDATED PART</H1></DIV><DIV class="row"><H4 class="para col-lg-12"><B><A href="http://parts.igem.org/Part:BBa_K2229400">BBa_K2229400</A> expresses Proteorhodopsin (PR),</B> a membrane protein capable of binding to citrate. It is one of our two approaches designed to trap citrate-capped nanoparticles. <B>We show experimentally that BBa_K2229400 binds to 60 nm citrate-capped silver nanoparticles</B> (CC-AgNPs).
                        </H4></DIV></HEADER><SECTION class="main"><DIV class="row" id="BBa"><H1 class="col-lg-12 title2">BBa_K2229400</H1></DIV><DIV class="row"><H4 class="para col-lg-12">
                            We obtained the DNA sequence for the <I>pR</I> gene, (Syed 2011) and modified it to remove three internal cutting sites (EcoRI, PstI, and SpeI). The sequence of <I>pR</I> was then flanked by an upstream strong promoter and strong ribosome combination (BBa_K880005), and a downstream double terminator (BBa_B0015) to maximize expression of PR protein. This final construct (BBa_K2229400; figure 2-2) was ordered from IDT and cloned into pSB1C3, a biobrick backbone. PCR checks (figure 2-4) and sequencing results from Tri-I Biotech confirmed that our final <I>pR</I> construct is correct. 
                        </H4></DIV><DIV class="row"><DIV class="image_container col-lg-8 col-lg-offset-2"><H4 class="subtitle"><B>Figure 2-2 Construct expressing PR. </B> Our construct includes a strong promoter, strong RBS, the <I>pR</I> ORF, and a double terminator.<SPAN class="subCred"> Figure: Justin Y.</SPAN></H4></DIV></DIV><DIV class="row"><DIV class="image_container col-lg-8 col-lg-offset-2"><H4 class="subtitle"><B>Figure 2-4. PCR Check for PR-expressing construct (BBa_K2229400) using the primers VF2 and VR. </B> The expected size of BBa_K2229400 is 1300 bp (green box).<SPAN class="subCred"> Cloning: Catherine Y., Dylan L.</SPAN></H4></DIV></DIV><DIV class="row" id="CR"><H1 class="col-lg-12 title2">Can Proteorhodopsin Bind Citrate-Capped Nanoparticles?</H1></DIV><DIV class="row"><H4 class="para col-lg-12">
                            Using a solution containing 60 nm CC-AgNPs (from Sigma Aldrich), we tested PRâ€™s ability to trap CC-NPs as we hypothesized. Because CC-AgNP solution is yellow in color, we can take absorbance measurements. Two groups were set up: <I>E. coli</I> carrying either BBa_K2229400 (PR expression construct; figure 2-2) or a negative control BBa_E0240 (GFP-generator) were grown in Luria-Bertani (LB) broth overnight. GFP-generator was used as a negative control because it does not express PR. The cultures were centrifuged, resuspended in distilled water to remove LB broth, and diluted to standardize bacterial population. Then, the cultures were mixed with CC-AgNP solution and shaken at 120 rpm. Every hour (for a total of 5 hours), one tube from each group was centrifuged at 4500 rpm to isolate the supernatant. At this speed, we observed that nearly all bacteria (and bound CC-AgNPs) were pulled down into the pellet while free CC-AgNPs remained in the supernatant, which was measured using a spectrophotometer at 430 nm.
                        </H4></DIV><DIV class="row"><DIV class="image_container col-lg-10 col-lg-offset-1"><H4 class="subtitle"><B>Figure 2-6 Proteorhodopsin traps CC-AgNPs. </B> A) Absorbance of the supernatant decreased markedly when PR bacteria was added to CC-AgNPs; the absorbance did not change significantly when GFP-Gen (negative control) bacteria was added. B) Over the 5 hour period, we observed a large orange region (aggregated CC-AgNPs) in the PR group.<SPAN class="subCred"> Experiment &amp; Figure: Justin Y.</SPAN></H4></DIV></DIV><DIV class="row"><H4 class="para col-lg-12">
                            Over 5 hours, we found that absorbance values of the supernatant decreased much faster when PR bacteria was added, while the absorbance did not change significantly when GFP-generator bacteria was added (figure 2-6A). In addition, after centrifugation, we saw dark orange regions in the pellet of PR bacteria, but not in the GFP-generator bacteria (figure 2-6B). CC-AgNP solution is yellow in color, which suggests that the orange regions observed in the PR pellet are aggregated CC-AgNPs. In summary, our results suggest that <B>PR is able to bind CC-AgNPs.</B></H4></DIV></SECTION></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></BODY></HTML>